SUNNYVALE, Calif., Oct. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, showcased new clinical research on its TomoTherapy® System at the 2012 TomoTherapy Asia Pacific Users' Meeting, which was held in conjunction with the Hong Kong Sanatorium & Hospital Scientific Meeting on Radiotherapy and TomoTherapy on September 21-23, 2012 in Hong Kong. The conference brought together approximately 130 TomoTherapy System users from across Asia Pacific for three days of education on the growing body of clinical evidence supporting the use of the TomoTherapy System for a wide range of clinical indications.
"On behalf of my colleagues from Hong Kong, I was honored to chair this year's TomoTherapy Asia Pacific Users' Meeting. During the meeting we facilitated the sharing of a broad range of clinical treatment experience using the TomoTherapy System," said Dr. Daniel Chua Tsin-Tien, associate director of Comprehensive Oncology Center of Hong Kong Sanatorium & Hospital. "I was thrilled by the breadth and depth of knowledge shared between peers on the use of the TomoTherapy System as well as the sustained advancement of the technology allowing us to provide the most optimal treatments to more patients."
"The participation of attendees from multiple countries in Asia Pacific underscores the continued momentum for the TomoTherapy System and further supports increased adoption throughout the region," said Bob Wong, managing director of Accuray Asia Pacific Region. "Over the past year, Accuray's business success has been bolstered by the joint effort with our partners in Asia Pacific and this June marked the one year anniversary of our acquisition of TomoTherapy Incorporated. We are proud of what we have accomplished to date, and most importantly reaffirm our commitment to not only achieving, but surpassing our users' expectations and goals."
Highlights of the Users' Meeting included an opening presentation by Dr. Kwan Wing-Hong on the role of radiation therapy and TomoHelicalTM in treating nasopharyngeal carcinoma and breast cancer patients at the Hong Kong Sanatorium & Hospital. Dr. Kwan's presentation was followed by a presentation from invited speaker Dr. Paul W. Read, associate professor and vice chairman, Department of Radiation Oncology of the University of Virginia Health System, USA. Dr. Read, who shared his clinical studies on STAT RAD: Development of a TomoTherapy® based Real Time Scan-Plan-QA-Treat Workflow. He indicated that this more efficient and cost effective workflow will result in more widespread incorporation of palliative radiation for bone metastases earlier in the disease process and pain reduction. Other invited speakers, included Prof. Rock Mackie from University of Wisconsin, Madison, USA, who presented his clinical evidence on the efficacy of the TomoTherapy System for its use on head and neck cancer. Prof Mackie summarized that treatment with the TomoTherapy System, with its unique MVCT-guided daily patient setup, enables smaller treatment margins, resulting in more dose to the tumor and enhanced normal tissue sparing.
Substantial clinical experience on the TomoTherapy System was also shared by leading hospitals in the region. This involved collaborative review and development of optimal treatment plans for four selected challenging clinical situations contributed from across the region.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company's leading edge technologies the CyberKnife and TomoTherapy Systems are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expansion of the Company's global presence, clinical research, clinical indications, availability of treatment, increase in adoption, user expectations, efficiency & cost effectiveness of workflows, clinical effectiveness, market adoption, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10,2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated